Back to search results

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hodgkin Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Illinois Cancer Center, Chicago, Illinois, United States

  • Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

  • University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

  • University of Minnesota, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Veronika Bachanova, MD) · bach0173@umn.edu · 612-625-5469
    Contact: Principal Investigator (Veronika Bachanova, MD)

  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Protocol Implementation Coordinator) · CTO.Implementation@osumc.edu · 614-293-3717
    Contact: Principal Investigator (Timothy Voorhees, MD)

  • University of Wisconsin, Madison, Wisconsin, United States

    Contact: Study coordinator (Kaitlin Chambers) · kchambers2@wisc.edu · 608-263-5006
    Contact: Principal Investigator (Vaishalee Kenkre, MD)
Study leads

  • Veronkia Bachanova, MD

    Principal Investigator

    University of Minnesota

View source on ClinicalTrials.gov(opens in a new tab)